Antihistamines Show Minimal Relief for Eczema Itch

New research shows that antihistamines do little to help eczema itch, challenging a common practice among dermatologists and allergists.

Study finds little benefit for itch relief

A systematic review of 47 randomized trials involving more than 6,200 children and adults concluded that antihistamines provide no meaningful improvement in eczema‑related itching. The analysis, led by Dr. Derek Chu, chair in allergy for the Canadian Institutes of Health Research, found that most patients would not notice a significant change in symptoms.

First‑generation antihistamines such as diphenhydramine showed no measurable effect on itch or overall eczema severity. Second‑generation drugs, including desloratadine and fexofenadine, produced modest changes that fell short of what clinicians consider clinically important.

The review also examined secondary outcomes. Antihistamines did not clearly improve sleep quality or reduce flare‑ups, and they were associated with side effects like drowsiness and slowed cognition, particularly with older agents.

Related: New ADHD Drug Gets Approval

Why doctors have used antihistamines

Historically, physicians prescribed antihistamines for eczema because itching can be driven by histamine in many allergic conditions. Over time, the practice became routine, even though the link between histamine and eczema itch was never firmly established.

Some clinicians also relied on the sedating properties of first‑generation antihistamines to help patients sleep through nighttime itching. Dr. Clinton Dunn, an allergist, noted that the approach was based on the assumption that reducing histamine would calm the itch.

Recent insights into eczema pathophysiology point to cytokine signaling. This shift has opened the door to newer treatments that target inflammatory pathways directly, such as JAK inhibitors and biologics that block interleukin‑13.

While the study emphasizes focusing on inflammation control, it does not suggest that antihistamines are universally useless. Patients with concurrent allergic rhinitis, hives, or other histamine‑mediated conditions may still benefit from these medications for those specific issues.

Looking ahead, the findings may prompt updates to clinical guidelines from major allergy and dermatology societies. Dr. Chu indicated that future recommendations will likely advise against routine antihistamine use for eczema, reserving them for cases where separate allergic diseases are present.

A cautious reading of the data suggests that clinicians should weigh the modest, if any, itch reduction against the potential for cognitive side effects, especially in children and older adults. As newer anti‑inflammatory options become more accessible, the reliance on antihistamines for eczema could diminish further.

In the United States, roughly 31.6 million people—about ten percent of the population—live with eczema. The condition’s intense itching can disrupt sleep, affect school or work performance, and strain mental health. Current treatment strategies emphasize moisturizers, topical anti‑inflammatory agents, and phototherapy to address the underlying skin inflammation.